These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 26088404)

  • 1. Patient reported health outcomes and non-adherence in psoriasis patients receiving adalimumab or ustekinumab for moderate to severe plaque psoriasis.
    Goren A; Carter C; Lee S
    J Dermatolog Treat; 2016; 27(1):43-50. PubMed ID: 26088404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterizing patients with psoriasis on injectable biologics adalimumab, etanercept, and ustekinumab: A chart review study.
    Zhang M; Goren A; Lee S; DiBonaventura MD; Olson WH
    J Dermatolog Treat; 2016 Aug; 27(4):339-45. PubMed ID: 26558924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of adalimumab versus ustekinumab in the treatment of severe chronic plaque psoriasis: The results based on data from the program "treatment of moderate and severe forms of plaque psoriasis (B.47)" of the National Health Fund in Poland.
    Owczarek W; Nowakowska A; Walecka I; Ciechanowicz P; Reich A; Lesiak A; Borkowska E; Śliwczyński A; Narbutt J
    Dermatol Ther; 2022 Jun; 35(6):e15481. PubMed ID: 35363386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients.
    Abrouk M; Nakamura M; Zhu TH; Farahnik B; Koo J; Bhutani T
    J Dermatolog Treat; 2017 Sep; 28(6):488-491. PubMed ID: 28042711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistency of Biologic Therapies for Plaque Psoriasis in 2 Large Community Practices.
    Verma L; Mayba JN; Gooderham MJ; Verma A; Papp KA
    J Cutan Med Surg; 2018; 22(1):38-43. PubMed ID: 29056080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan
    Leonardi C; Zhu B; Malatestinic WN; Eastman WJ; Guo J; Murage MJ; Choong CK; Burge R; Blauvelt A
    Adv Ther; 2022 Jul; 39(7):3214-3224. PubMed ID: 35570242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug Adherence and Persistence of Patients with Moderate to Severe Psoriasis Treated with Biologic Medications in a US Commercially Insured Population.
    Xu C; Teeple A; Wu B; Fitzgerald T; Feldman SR
    Dermatology; 2022; 238(3):438-447. PubMed ID: 34710876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and survival of biologic agents in psoriasis: a practical real-life 12-year experience in a French dermatology department.
    Roche H; Bouiller K; Puzenat E; Deveza E; Roche B; Pelletier F; van de Laak A; Dupond AS; Nardin C; Aubin F
    J Dermatolog Treat; 2019 Sep; 30(6):540-544. PubMed ID: 29848153
    [No Abstract]   [Full Text] [Related]  

  • 9. Biologic treatment sequences for plaque psoriasis: a cost-utility analysis based on 10 years of Dutch real-world evidence from BioCAPTURE.
    Klijn SL; van den Reek JMPA; van de Wetering G; van der Kolk A; de Jong EMGJ; Kievit W
    Br J Dermatol; 2018 May; 178(5):1181-1189. PubMed ID: 29247500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).
    Strober BE; Bissonnette R; Fiorentino D; Kimball AB; Naldi L; Shear NH; Goyal K; Fakharzadeh S; Calabro S; Langholff W; You Y; Galindo C; Lee S; Lebwohl MG
    J Am Acad Dermatol; 2016 May; 74(5):851-61.e4. PubMed ID: 26853180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching to risankizumab from ustekinumab or adalimumab in plaque psoriasis patients improves PASI and DLQI outcomes for sub-optimal responders.
    Strober B; Armstrong A; Rubant S; Patel M; Wu T; Photowala H; Crowley J
    J Dermatolog Treat; 2022 Nov; 33(7):2991-2996. PubMed ID: 35839335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Healthcare resource utilization, healthcare costs and dose escalation in psoriasis patients initiated on ustekinumab versus adalimumab: a retrospective claim study.
    Wu JJ; Guérin A; Gauthier G; Sundaram M
    J Dermatolog Treat; 2017 Jun; 28(4):290-298. PubMed ID: 27783534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative real-world outcomes between ustekinumab, infliximab, and adalimumab in bio-naïve and bio-experienced Crohn's disease patients: a retrospective multicenter study.
    Na JE; Park YE; Park J; Kim TO; Lee JH; Park SB; Kim S; Lee SB;
    BMC Gastroenterol; 2024 Sep; 24(1):306. PubMed ID: 39261766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching biologics in children with psoriasis: Results from the BiPe cohort.
    Phan C; Beauchet A; Reguiai Z; Severino-Freire M; Mazereeuw-Hautier J; Bursztejn AC; Barbarot S; Hadj-Rabia S; Girard C; Phan A; Lacour JP; Lasek A; Abasq C; Brenaut E; Perrussel M; Droitcourt C; Mallet S; Piram M; Fougerousse AC; Barthélémy H; Balguérie X; Mahé E;
    Pediatr Dermatol; 2022 Jan; 39(1):35-41. PubMed ID: 34888920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient Preference for Dosing Frequency Based on Prior Biologic Experience.
    Zhang M; Carter C; Olson WH; Johnson MP; Brennem SK; Lee S; Farahi K
    J Drugs Dermatol; 2017 Mar; 16(3):220-226. PubMed ID: 28301617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis.
    Iskandar IYK; Ashcroft DM; Warren RB; Lunt M; McElhone K; Smith CH; Reynolds NJ; Griffiths CEM
    Br J Dermatol; 2017 Nov; 177(5):1410-1421. PubMed ID: 28369707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Tightly Controlled Dose Reduction of Biologics With Usual Care for Patients With Psoriasis: A Randomized Clinical Trial.
    Atalay S; van den Reek JMPA; den Broeder AA; van Vugt LJ; Otero ME; Njoo MD; Mommers JM; Ossenkoppele PM; Koetsier MI; Berends MA; van de Kerkhof PCM; Groenewoud HMM; Kievit W; de Jong EMGJ
    JAMA Dermatol; 2020 Apr; 156(4):393-400. PubMed ID: 32049319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database.
    Sruamsiri R; Iwasaki K; Tang W; Mahlich J
    BMC Dermatol; 2018 Jul; 18(1):5. PubMed ID: 29996929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse Medical Conditions Across Treatment Options in Patients With Psoriasis: A Claims-Based Analysis.
    Wu JJ; Armstrong A; Singh R; Cloutier M; Gauthier-Loiselle M; Gagnon-Sanschagrin P; Arikan D; Fleischer A; Guérin A; Ganguli A
    J Drugs Dermatol; 2018 Nov; 17(11):1211-1218. PubMed ID: 30500143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment adherence and persistence of seven commonly prescribed biologics for moderate to severe psoriasis and psoriatic arthritis in a U.S. commercially insured population.
    Xu C; Teeple A; Wu B; Fitzgerald T; Feldman SR
    J Dermatolog Treat; 2022 Jun; 33(4):2270-2277. PubMed ID: 34264149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.